Mackenzie Financial Corp Has $152.04 Million Stock Position in Charles River Laboratories International, Inc. $CRL

Mackenzie Financial Corp cut its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,002,049 shares of the medical research company’s stock after selling 902 shares during the quarter. Mackenzie Financial Corp’s holdings in Charles River Laboratories International were worth $152,041,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC boosted its holdings in Charles River Laboratories International by 1.3% during the second quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock valued at $871,000 after acquiring an additional 76 shares during the period. Brooklyn Investment Group lifted its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Charles River Laboratories International by 1.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock valued at $1,072,000 after purchasing an additional 86 shares during the period. WESCAP Management Group Inc. grew its holdings in Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company’s stock valued at $371,000 after buying an additional 89 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in Charles River Laboratories International by 0.7% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company’s stock valued at $2,553,000 after buying an additional 109 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 0.4%

CRL opened at $178.14 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $203.01. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The firm’s fifty day moving average price is $171.68 and its two-hundred day moving average price is $160.16. The company has a market capitalization of $8.77 billion, a P/E ratio of -133.94, a P/E/G ratio of 4.83 and a beta of 1.53.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. During the same quarter in the prior year, the company posted $2.59 EPS. The business’s revenue was down .5% on a year-over-year basis. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRL. Baird R W upgraded Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. TD Cowen dropped their target price on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Barclays upped their target price on shares of Charles River Laboratories International from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their price target for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Finally, Robert W. Baird upgraded shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $178.00 to $199.00 in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $190.86.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).